



HAL
open science

Genotype–phenotype correlations and novel molecular insights into the DHX30-associated neurodevelopmental disorders

Ilaria Mannucci, Nghi D P Dang, Hannes Huber, Jaclyn B Murry, Jeff Abramson, Thorsten Althoff, Siddharth Banka, Gareth Baynam, David Bearden, Ana Beleza-Meireles, et al.

► **To cite this version:**

Ilaria Mannucci, Nghi D P Dang, Hannes Huber, Jaclyn B Murry, Jeff Abramson, et al.. Genotype–phenotype correlations and novel molecular insights into the DHX30-associated neurodevelopmental disorders. *Genome Medicine*, 2021, 13 (90), 10.1186/s13073-021-00900-3 . hal-04538727

HAL Id: hal-04538727

<https://hal.sorbonne-universite.fr/hal-04538727>

Submitted on 9 Apr 2024

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

RESEARCH

Open Access



Genotype–phenotype correlations and novel molecular insights into the *DHX30*-associated neurodevelopmental disorders

Ilaria Mannucci¹, Nghi D. P. Dang², Hannes Huber³, Jaclyn B. Murry^{4,5}, Jeff Abramson⁶, Thorsten Althoff⁶, Siddharth Banka^{7,8}, Gareth Baynam^{9,10,11}, David Bearden¹², Ana Belezza-Meireles¹³, Paul J. Benke¹⁴, Siren Berland¹⁵, Tatjana Bierhals¹, Frederic Bilan^{16,17}, Laurence A. Bindoff^{18,19}, Geir Julius Braathen²⁰, Øyvind L. Busk²⁰, Jirat Chenbhanich²¹, Jonas Denecke²², Luis F. Escobar²³, Caroline Estes²³, Julie Fleischer²⁴, Daniel Groepper²⁴, Charlotte A. Haaxma²⁵, Maja Hempel¹, Yolanda Holler-Managan²⁶, Gunnar Houge¹⁵, Adam Jackson^{7,8}, Laura Kellogg²⁷, Boris Keren²⁸, Catherine Kiraly-Borri²⁹, Cornelia Kraus³⁰, Christian Kubisch¹, Gwenael Le Guyader^{16,17}, Ulf W. Ljungblad³¹, Leslie Manace Brenman³², Julian A. Martinez-Agosto^{5,33,34,35}, Matthew Might³⁶, David T. Miller³⁷, Kelly Q. Minks¹², Billur Moghaddam²⁷, Caroline Nava²⁸, Stanley F. Nelson^{5,35,38}, John M. Parant², Trine Prescott²⁰, Farrah Rajabi³⁷, Hanitra Randrianaivo³⁹, Simone F. Reiter¹⁵, Janneke Schuurs-Hoeijmakers⁴⁰, Perry B. Shieh⁴¹, Anne Slavotinek²¹, Sarah Smithson¹³, Alexander P. A. Stegmann^{40,42}, Kinga Tomczak⁴³, Kristian Tveten²⁰, Jun Wang², Jordan H. Whitlock³⁶, Christiane Zweier^{30,44}, Kirsty McWalter⁴⁵, Jane Juusola⁴⁵, Fabiola Quintero-Rivera^{4,5,46}, Utz Fischer³, Nan Cher Yeo^{2*}, Hans-Jürgen Kreienkamp^{1*} and Davor Lessel^{1*} 

Abstract

Background: We aimed to define the clinical and variant spectrum and to provide novel molecular insights into the *DHX30*-associated neurodevelopmental disorder.

Methods: Clinical and genetic data from affected individuals were collected through Facebook-based family support group, GeneMatcher, and our network of collaborators. We investigated the impact of novel missense variants with respect to ATPase and helicase activity, stress granule (SG) formation, global translation, and their effect on embryonic development in zebrafish. SG formation was additionally analyzed in CRISPR/Cas9-mediated *DHX30*-deficient HEK293T and zebrafish models, along with in vivo behavioral assays.

(Continued on next page)

* Correspondence: nyeo@uab.edu; kreienkamp@uke.de; d.lessel@uke.de

²Department of Pharmacology and Toxicology, University of Alabama, Birmingham, USA

¹Institute of Human Genetics, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany

Full list of author information is available at the end of the article



© The Author(s). 2021 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

(Continued from previous page)

Results: We identified 25 previously unreported individuals, ten of whom carry novel variants, two of which are recurrent, and provide evidence of gonadal mosaicism in one family. All 19 individuals harboring heterozygous missense variants within helicase core motifs (HCMs) have global developmental delay, intellectual disability, severe speech impairment, and gait abnormalities. These variants impair the ATPase and helicase activity of DHX30, trigger SG formation, interfere with global translation, and cause developmental defects in a zebrafish model. Notably, 4 individuals harboring heterozygous variants resulting either in haploinsufficiency or truncated proteins presented with a milder clinical course, similar to an individual harboring a de novo mosaic HCM missense variant. Functionally, we established DHX30 as an ATP-dependent RNA helicase and as an evolutionary conserved factor in SG assembly. Based on the clinical course, the variant location, and type we establish two distinct clinical subtypes. *DHX30* loss-of-function variants cause a milder phenotype whereas a severe phenotype is caused by HCM missense variants that, in addition to the loss of ATPase and helicase activity, lead to a detrimental gain-of-function with respect to SG formation. Behavioral characterization of *dhx30*-deficient zebrafish revealed altered sleep-wake activity and social interaction, partially resembling the human phenotype.

Conclusions: Our study highlights the usefulness of social media to define novel Mendelian disorders and exemplifies how functional analyses accompanied by clinical and genetic findings can define clinically distinct subtypes for ultra-rare disorders. Such approaches require close interdisciplinary collaboration between families/legal representatives of the affected individuals, clinicians, molecular genetics diagnostic laboratories, and research laboratories.

Background

RNA helicases (RH) are highly specialized proteins which use ATP hydrolysis for the unwinding of RNA secondary structures and the remodeling of ribonucleoprotein particles (RNPs) [1, 2]. RHs are classified into six known superfamilies based on their sequence and structure [1]. Among these, the large helicase superfamily 2 (SF2) contains more than 50 members in humans [3]. These are designated DDX and DHX proteins based on the consensus amino acid sequence DExD or DExH signature in their ATP-binding motif II (Walker B motif) [3]. All SF2 RNA helicases are built around a highly conserved helicase core region consisting of two domains that resemble the bacterial recombination protein recombinase A (referred to as RecA-1 and RecA-2). Within these two core helicase domains, eight highly conserved sequence elements, helicase core motifs (HCMs) play a role in either RNA binding, or ATP binding and hydrolysis. The roles of SF2 RNA helicases include regulation of splicing, nuclear mRNA export, translation, transcription, facilitation of mRNA decay, microRNA processing, and cytoplasmic transport and storage of RNAs [1]. So far, many of the RHs have been studied in various cancers revealing the role of translation in carcinogenesis [4], and serve as potential biomarkers for diagnosis and prognosis, and novel drug targets [5]. The importance and functional relevance of certain SF2 RHs in human neurodevelopment is demonstrated by the identification of pathogenic germline variants in *DDX3X* [6], *DDX6* [7], *DHX30* [8], and *DDX5* [9] in individuals with neurodevelopmental disorders. Additionally, a paralog-based study implicated a role for *DHX16*, *DHX34*, *DHX37*, and *DDX54*, in human neurodevelopmental disorders and suggested that *DHX8*, *DDX47*, and *DHX58* may also be neurodevelopmental genes [10].

Previously, we reported 12 unrelated individuals with global developmental delay (GDD), intellectual disability (ID) accompanied by severe speech impairment and gait abnormalities, harboring one of six different de novo missense variants located within highly conserved HCMs of *DHX30* [8]. Moreover, a recent study reported gonadal mosaicism in two brothers carrying a de novo missense variant, p.(Ser737Phe), which resides within a HCM [11]. Here, we performed clinical, genetic, and functional analyses to provide further understanding of *DHX30*-related neurodevelopmental disorders through the identification of 25 previously unreported individuals. This systematic clinical and research approach, partially facilitated through social media, establishes novel genotype-phenotype correlations based on *in-depth* functional analyses accompanied by clinical and genetic findings.

Methods

Human subjects and genetic analyses

Written informed consent for all 25 subjects was obtained from the parents or legal guardians in accordance with protocols approved by the respective ethics committees of the institutions involved in this study. Next-generation sequencing-based analyses were performed in various independent research or diagnostic laboratories worldwide, using previously described procedures [8, 12–16]. Trio-whole exome sequencing (WES) was performed in families of subjects 1, 4, 5, 6, 10, 11, 13, 14, 15, 17, 18, 19, 20, 21, 22, and 23. Single WES was performed in subjects 2, 3, 8, 16, and 25. Targeted Sanger sequencing was performed in subject 9, half-sister of subject 8. For subject 7, WES was performed as duo with DNA sample of his mother. Trio-whole genome

sequencing (WGS) in family of the subject 12 was done on an Illumina system using Nextera DNA Flex Library Prep. Reads were aligned to human genome build GRCh38 and analyzed for sequence variants using Cpipe analysis tool [17]. Classification the identified variants was based on the American College of Medical Genetics and Genomics (ACMG) guidelines [18]. Clinical Chromosomal Microarray analysis in family 24 was performed using standardized platforms [19]. Interpretation of identified copy number variants followed ACMG guidelines [20]. Most individuals were enrolled in the present study through the “*DHX30 family support group*” on Facebook: <https://www.facebook.com/groups/1808373282809332>. In such a case the families/legal representatives were asked to provide the contact details of attending physicians in order to obtain objective and accurate clinical and genetic data. Others presented in the University Medical Center Hamburg-Eppendorf, Hamburg, Germany, or were recruited through GeneMatcher [21] and our network of collaborators. For all 25 individuals, clinical data and information on genetic testing were uniformly obtained from attending physicians using a structured clinical summary (Additional file 1) and clinical table (Additional file 2: Table S1).

Cell culture and *in-vitro* assays

Human embryonic kidney 293 T (HEK 293 T) cells and human bone osteosarcoma epithelial (U2OS) cells were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS) as described previously [8]. *DHX30* expression vectors based on pEGFP-C3 (leading to an N-terminal GFP-tag) and pEGFP-N2 (for expression of the mitochondrial form of *DHX30* with a C-terminal GFP-tag) have been described previously [8]. Newly identified missense variants were introduced into both vectors using Quick-Change II site-directed mutagenesis kit (Agilent, Waldbronn, Germany). HEK293T and U2OS cells were transfected with TurboFect or Lipofectamine 2000, respectively, transfection reagent (ThermoFisher Scientific) according to the manufacturer's recommendations. Immunocytochemistry and puromycin incorporation assay in U2OS cells were performed utilizing the following antibodies at manufacturers' recommended dilutions: anti-Puromycin mouse monoclonal (Millipore, #MABE343); goat anti-mouse coupled to Alexa Fluor 555 (ThermoFisher Scientific). A custom made anti-ATXN2 (#8G3, kindly provided by Dr. S. Kindler, Human Genetics, UKE; Hamburg) rat monoclonal antibody was used at a 1:10 dilution as previously described [8]. ATPase assay was performed as previously described [8]. Briefly, after transfection of HEK293T cells with *DHX30* expression vectors, followed by lysis in 1 ml of radioimmunoprecipitation assay buffer (RIPA), the lysates were clarified by centrifugation at 20,000×g for 20

min at 4 °C. GFP-containing proteins were purified from the supernatant by immunoprecipitation using 20 µl of GFP-Trap_A matrix (Chromotek, Munich, Germany). Precipitates were washed twice in RIPA buffer, and twice in phosphate-free ATPase assay buffer (40 mM KCl; 35 mM HEPES pH 7.5; 5 mM MgCl₂; prepared in plastic ware to avoid phosphate contamination). Precipitates were then incubated in 50 µl phosphate-free buffer supplemented with 2 mM ATP and 2 mM DTT at 30 °C for 30 min (for assaying ATPase activity in the absence of exogenous RNA). After brief centrifugation (1 min, 1000×g), the supernatant was removed and precipitated samples were incubated in phosphate-free buffer containing 2 mM ATP; 2 mM DTT, and 100 µg/ml yeast RNA for 30 min at 30 °C (for assaying ATPase activity in the presence of exogenous RNA). The amount of free phosphate released by ATP hydrolysis was determined photometrically using Biomol Green reagent (Enzo Life Sciences, Lörrach, Germany). Subsequently, bead-attached proteins were denatured in SDS-sample buffer, and the amount of *DHX30* protein was determined by western blotting using anti-GFP (Covance). In each case, ATPase activity was normalized to the amount of GFP-tagged *DHX30* protein attached to the GFP-trap matrix.

Helicase assay

6xHis-SUMO-*DHX30* wild-type and mutant proteins were expressed in the *E. coli* BL21 (DE3) pLysSpRARE cells (Novagen, Germany). Proteins were purified from lysates using Ni-NTA beads (Qiagen, Germany) as previously described [22]. To test the RNA unwinding activity of *DHX30*, a [³²P]-labeled RNA duplex was synthesized using the T7 RNA polymerase from a linearized DNA template designed by Tseng-Rogenski and Chang [23]. Helicase activity was measured in 20 µl of reaction mixture containing 0.13 pmol of purified protein (=20 ng of full-length protein), 25 fmol [³²P]-labeled RNA duplex, 17 mM HEPES-KOH pH 7.5, 150 mM NaCl, 1 mM MgCl₂, 2 mM DTT, 1 mM spermidine, 0.3% PEG8000, 5% glycerol, 150 mM KCl, 20 units of RNasin™ Plus (Promega, USA), 1 mM ATP. The mixture was incubated for 1 h at 37 °C, mixed with 2X non-denaturing loading dye and subjected to gel electrophoresis through non-denaturing 8% PAGE (19:1) in 0.5X TBE at 4 °C. Reaction products were visualized by autoradiography. For more information see Additional file 1: Supplementary methods.

Generation of a HEK293T *DHX30* stable knockout line

HEK293T *DHX30*-deficient cells were generated by transfecting a plasmid (pLentiCRISPR v2, GenScript, #52961) encoding a single guide RNA (CGAGTGCTAG CTGATCGCTT) targeting exon 7, the Cas9 endonuclease and a puromycin resistance gene under the control of the EFS promoter. Cells were transfected with

TurboFect transfection reagent (Thermo Scientific) and treated with puromycin for 3 days. Surviving cells were then subjected to single cell sorting using BD FACS Aria™ IIIu Cell Sorter (BD Biosciences). Single-cell clones were grown in 96-well plates for two weeks and then expanded into 6 well dishes. DHX30 knockout efficiency was assessed by Western blotting using an anti-DHX30 rabbit polyclonal antibody (Bethyl, #A302-218A) (1:500).

Stress treatment

HEK293T WT and *DHX30*-deficient cells were plated on glass coverslips coated with poly-L-Lysine. After 24 h, cells were heat stressed at 43.5 °C for 1 h, fixed in 4% paraformaldehyde and permeabilized with 0.1% Triton X-100 (Sigma). Blocking was performed using 10% horse serum (HS). Rat monoclonal anti-ATXN2 was used as a primary antibody (1:10 in 2 % HS in PBS), followed by goat anti-rat IgG coupled to Alexa Fluor 647 (Thermo Fisher Scientific). Coverslips were mounted on glass microscope slides with ProLong Diamond Antifade Mountant with DAPI (Thermo Fisher Scientific). Immunofluorescence images were acquired using a confocal microscope (Leica TCS SP5, 63x/1.25 objective) and processed with ImageJ software.

Construction of Tol2 plasmids

DHX30 cDNA plasmids were assembled using the Tol2 MultiSite Gateway® kit (Invitrogen, USA). Briefly, the cDNA of the wild-type DHX30 and DHX30 containing respective missense variants were amplified from the pEGFP-C3-DHX30 plasmids, using primers containing the appropriate att site sequences for BP recombination reactions. PCR products were purified and cloned into a pDONR221 donor vector using BP Clonase II enzyme mix following the manufacturer's manual. The resulting middle entry clones pME-DHX30 were purified and verified by direct sequencing. To assemble the final expression plasmids, p5E-tuba1a promoter and pME-DHX30 were cloned into a Tol2-based destination vector, pDest-Tol2CG2 containing *cmlc2:EGFP* transgenesis marker, using LR Clonase II Plus enzyme mix following the manufacturer's instructions. The resultant pTol2pA2-*cmlc2:EGFP;tuba1a:DHX30* vectors were purified and verified by direct sequencing.

Zebrafish maintenance and manipulation

Tol2 transposase mRNA were synthesized using mMES-SAGE mMACHINE™ T7 Transcription Kit (Ambion) per the manufacturer's instructions. Twenty-five nanograms/μl Tol2 mRNA and 25 ng/μl of pTol2pA2-*cmlc2:EGFP;tuba1a:DHX30* DNA were injected into 1-cell stage zebrafish embryos (Danio rerio AB strain). To investigate a potential dominant-negative effect, 25 ng/μl

Tol2 mRNA and 25 ng/μl equal mixture of pTol2pA2-*cmlc2:EGFP;tuba1a:DHX30* with the respective variant DNA were injected into 1-cell stage zebrafish embryos. The embryos were raised and scored for abnormal development 1–7 days post fertilization. Zebrafish were maintained in the Zebrafish Research Facility at the University of Alabama at Birmingham using standard protocols. All fish were maintained at 28 °C and kept at 14-h light and 10-h dark cycle under standard laboratory conditions.

Generation of zebrafish *dhx30* stable knockout line

The zebrafish *dhx30* stable knockout line was generated using CRISPR/Cas9 with sgRNA target sequence 5'-TCAAGTTCAGCTGCACGGAT-3' made by Integrated DNA Technologies (IDT) according to the manufacturer's protocol. The mutant contains an 8-bp deletion that shifts the translational reading frame after amino acid 90 and results in a premature stop codon at amino acid 107, compared to 1173 amino acids for the wild-type (WT) protein. Mutant animals were genotyped and sequenced using primers 5'-ATCTTCACGCCAAAAA CCTG-3' and 5'-GACCACGGTTCAGCTCTCTC-3'. The *dhx30* heterozygous mutants were outcrossed to the parental AB strain for at least two generations before use in experiments to eliminate potential off-target variants. After each assay described below, test animals were individually genotyped using PCR with primers 5'-ATCTTCACGCCAAAAACCTG-3' and 5'-GACCACGGTTCAGCTCTCTC-3' and high-resolution melting (HRM) analysis as previously described [24].

Stress treatment and zebrafish whole-mount immunostaining

The *dhx30* +/- animals were in-crossed to generate *dhx30* +/+, +/-, and -/- sibling progeny for heat shock and immunostaining analyses. Twenty-four-hour post-fertilization embryos were dechorionated and incubated at 28 °C or 42 °C for 1 h. After treatment, embryos were fixed overnight in cold 4% paraformaldehyde (PFA). Embryos were then dehydrated with acetone at -20 °C for 7 min, washed in PBST [PBS+ 0.1% Tween 20], and blocked with 10% goat serum for at least 1 h at room temperature. Thereafter, embryos were incubated with rabbit anti-TIAL-1 (Novus Biologicals, NBP1-79932; 1:200) overnight at 4 °C, washed with PBST, and incubated with secondary antibody Alexa Fluor 488-conjugated goat anti-rabbit IgG (Invitrogen, A11034; 1:200) for 2 h at room temperature. Embryos were washed with PBST, incubated with 100 μM DAPI (1:500) to counterstain nuclei for 10 min, and stored in PBS at 4 °C. For imaging, stained embryos were mounted in 1% low melting agarose and imaged using a Nikon A1 inverted confocal microscope at approximately 50-μm Z-stacks at 5.6 μm

intervals. The number of TIAL-1-labeled stress granules per 50 nuclei was quantified using Nikon NIS Element. After imaging, test animals were individually genotyped by PCR and HRM analysis to delineate the *dhx30* genotype.

Behavioral assays

For each behavioral experiment, *dhx30* +/- animals were in-crossed to generate *dhx30* +/+, +/-, and -/- sibling progeny.

Twenty-four-hour sleep-wake activity

For each sleep-wake study, zebrafish larvae at 5-day post-fertilization (dpf) were chosen randomly and placed individually into each well of a flat-bottom 24-well plate. The activity of each larva was tracked for 24 h consisting of 14-h light and 10-h dark using the DanioVision system (Noldus Information Technology). The average swimming distance was measured for 24 h per 1-h time-bins using EthoVision XT software (Noldus).

Social preference assay (SPA)

We adopted and modified a previously described social preference assay (SPA) [25]. Briefly, SPA was performed using a flat-bottom 12-well plate and custom-built removable opaque dividers. The individual “test” animals, whose behaviors were analyzed, were placed in each of the 4 middle wells of the plate, and a WT conspecific of similar age and size was placed in a well either above or below each middle well. The activity of each test larva was tracked using the DanioVision (Noldus Information Technology) system and data analyzed using EthoVision XT software (Noldus). Before data acquisition, animals were given 5-min habituation period. The “baseline” activity of the test fish was then recorded while the opaque dividers were inserted between each well to prevent the animals from seeing each other. The dividers were then removed, allowing each test animal to view one well containing a conspecific animal and one empty well. The fish were given another 5-minute habituation period, followed by a 10-min “post-baseline” recording. For data analyses, wells containing test fish were divided into two 0.5 cm × 2.2 cm zones, one closest to the well containing a conspecific animal and one closest to the empty well. The amount of time spent by a test fish in each zone during the baseline and post-baseline periods was analyzed. The social preference of each test fish was quantified by calculating the social preference index (SPI) = (time spent in zone near the conspecific fish – time spent in zone near the empty well)/time spent in both zones as previously described [25].

Statistical analyses


All cell line data (U2OS and HEK293T) are presented as mean ± SD and analyzed by One-Way ANOVA followed by Dunnett’s multiple comparisons test or unpaired Student’s *t* test as indicated in figure descriptions. All zebrafish-related data are presented as mean ± SEM and analyzed by unpaired Student’s *t* test. The percentage of developmental defects observed upon overexpression of *dhx30* was analyzed by the χ^2 test.

Results

Identification of likely causative variants in *DHX30*

We identified 25 individuals carrying likely causative variants in *DHX30* (Fig. 1). Of these, 12 individuals carry a previously reported heterozygous missense variant localizing within highly conserved helicase core motifs (HCMs): p.(Arg493His), p.(His562Arg), p.(Arg782Trp) (5 individuals including two half-sisters indicative of gonadal mosaicism), p.(Arg785Cys) (4 individuals), and p.(Arg785His). Further, 7 individuals have a novel heterozygous missense variant classified as either “likely pathogenic” or “pathogenic” according to The American College of Medical Genetics and Genomics (ACMG) guidelines (Additional file 2: Table S1) [18]. Indeed, each of these variants alters a highly conserved amino acid within a HCM predicted to be responsible for ATP binding and/or hydrolysis (Fig. 1 and Additional file 3: Figure S1). p.(Gly462Glu) identified in a single individual affects motif I, also referred to as Walker A motif, that binds γ phosphate and coordinates, together with motifs II and VI, ATP binding and hydrolysis in other DEXH family members [26, 27]. p.(Ala734Asp) identified in two unrelated individuals, one of which (individual 6) appears to have mosaicism for the variant (Additional file 4: Figure S2), and p.(Thr739Ala) identified in a single individual, both affect motif V which regulates both ATP binding and/or hydrolysis and RNA binding [2, 27]. Three individuals carry p.(Arg782Gln), located within motif VI affecting the identical arginine residue (Arg782), that we previously reported p.(Arg782Trp) [8], which was identified here in five additional individuals.

Moreover, a homozygous variant p.(Arg725His) located within the helicase core region albeit between motifs IV and V, unlike all the missense variants mentioned above, was identified in individual 4 and classified as “variant of uncertain significance”. Additionally, a heterozygous *de novo* variant p.(Arg908Gln) was identified in individual 21. This was the only variant not located within the helicase core region and was classified as “likely pathogenic”. Predictions based on homology to other SF2 helicases [26, 28] and published structures of the Prp43 [29] and Mle [30] revealed three novel highly conserved C-terminal regulatory domains (CTD). These include a winged helix (WH), a ratchet-like (RL) and an



oligosaccharide binding (OB) fold domain (Fig. 1) with a potential role in coupling ATP hydrolysis to RNA unwinding [31]. Notably, the p.(Arg908Gln) affects a highly conserved residue within the RL domain (Figure S1).

Furthermore, we identified four individuals bearing likely pathogenic loss-of-function variants. A heterozygous de novo frameshift variant, p.(Ala116Valfs*12) in individual 22, a heterozygous nonsense variant, p.(Arg797*) in individual 23 inherited from a mosaic mother, and a *de novo* in-frame deletion encompassing exons 7-9 of *DHX30*, leading to deletion of 381 amino acids, in individual 25. Individual 24 has a large heterozygous de novo deletion (arr[GRCh37] 3p21.31 (47098509_48109065)del) encompassing ten genes including two disease genes previously associated with an autosomal dominant inheritance, *SETD2* [32–34] and *DHX30* (Fig. 1b and Additional file 5: Figure S3), possibly pointing to a dual diagnosis. The whole gene deletion results in haploinsufficiency, whereas the in-frame deletion, frameshift, and nonsense variant, if they were to result in stable proteins, are predicted to lead to loss of functionally important domains (Fig. 1a).

Notably, none of these *DHX30* alterations was present in the gnomAD dataset v2.1.1 (Additional file 2: Table S1) [35], indicating that they are extremely rare in the population and unlikely to be variants unrelated to disease. As previously noted, *DHX30* is one of the most missense-intolerant genes in the human genome [8]. Furthermore, according to the gnomAD v2.1.1 dataset

DHX30 is, with a probability of being loss-of-function intolerant (pLI) score of 1 and a loss-of-function observed/expected upper bound fraction (LOEUF) score of 0.04, extremely loss-of-function intolerant [35]. Additionally, the degree of intolerance to deleterious variants of *DHX30* according to the Residual Variation Intolerance (RVI) score, which quantifies gene intolerance to functional variants, is -1.51 (3.54th percentile) and thus even lower than the average RVI score for genes involved in developmental disorders (0.56; 19.54th percentile) [36, 37].

Clinical spectrum of the *DHX30*-associated neurodevelopmental disorders

All 19 individuals harboring a heterozygous missense variant within a highly conserved motif in the helicase core domain have global developmental delay (GDD), intellectual disability (ID), severe speech impairment, and gait abnormalities, similar to our initial findings [8]. In more detail, all individuals had an intellectual disability, only nine (47%) learned to walk, all with an ataxic gait. The majority had no speech (74%), four individuals spoke only single words, and only individual 6, who is mosaic for the de novo p.(Ala734Asp) variant, spoke simple sentences. It is worth noting that the individuals highly benefit from communication devices (tablets, smartphones, and eye-driven tablet communication systems) which significantly reduced frustration-related

behavior (D.L. personal communication with legal guardians and family members). Additional phenotypic features included muscular hypotonia in eighteen (95%), feeding difficulties in sixteen (84%), microcephaly in thirteen (81%, 13/16), joint hypermobility in fourteen (74%), structural brain anomalies in eleven (65%, 11/17), sleep disturbances in nine (47%), strabismus in eight (42%), autistic features in five (33%, 5/15), and seizures in four (21%) individuals (Table 1, Additional file 2: Table S1 and Additional file 6). Noteworthy, individual 6 had a relatively milder clinical course, with a moderate intellectual disability, independent walking at 2 years and 8 months, and the ability to speak in simple sentences at the age of 15 years. This individual's presentation is similar to that of the four individuals (#22, #23, #24, and #25), who carry either a frameshift or nonsense variant, whole-gene deletion or in-frame deletion, respectively, who all learned to walk in the second year of life, had a mild muscular hypotonia and spoke at least 20 words by the age of 3 years. Although some individuals displayed some dysmorphic features (Additional file 6) we did not

observe a recognizable facial gestalt, similar to our previous findings [8].

Two individuals (#4 and #21) clearly stand out phenotypically. Individual 4 was homozygous for p.(Arg725His), developed early-onset infantile epileptic encephalopathy, and died at 11 months. In contrast, individual 21, who harbors the de novo p.(Arg908Gln) variant, had unremarkable psychomotor development until the age of 8 years when she presented with progressive balance impairment with truncal ataxia. Subsequently, she experienced a decline in motor skills and developed cognitive problems with reduced concentration (Table 1, Additional file 2: Table S1 and Additional file 6).

Effect of novel *DHX30* missense variants on ATPase activity

To corroborate the pathogenicity of the novel missense variants identified in this study, along with the recently reported p.(Ser737Phe) [11], we performed several previously established functional assays [8]. First, we analyzed the ATPase activity of wild-type (WT) and mutant forms of *DHX30*. As

Table 1 Clinical features in 25 individuals bearing pathogenic *DHX30* variants and frequency of these features in previously reported individuals

<i>DHX30</i> variant	Heterozygous missense variants within a HCM (this study)	p.(Ala734Asp) mosaic (this study)	Haploinsufficiency/protein truncating variants (this study)	Homozygous p.(Arg725His) (this study)	Heterozygous p.(Arg908Gln) (this study)	Heterozygous missense variants within a HCM (previous studies: Lessel et al. 2017 and Cross et al. 2020)
Sex	11 females/7 males	Female	1 female/3 males	Male	Female	8 females/6 males
Intellectual disability	18/18	+	4/4	?	–	13/13
Speech ability	14/18 non-verbal 4/18 single words	Simple sentences	20 words to normal speech ability	?	Normal speech ability	11/13 non-verbal 2/13 single words
Motor development delay	18/18	+	4/4 mild	+	–	14/14
Muscular hypotonia	17/18	+	3/4	+	–	14/14
Gait abnormalities	10/18 no independent walking 8/18 ataxic	Ataxic gait	0/4 no independent walking 3/4 ataxic gait	?	Ataxic gait	7/13 no independent walking 6/13 ataxic gait
Feeding difficulties	15/18	+	1/4	+	–	11/14
Microcephaly	13/15	+	0/4	–	–	7/10
Joint hypermobility	13/18	+	1/3	–	–	6/14
Brain MRI anomalies	11/17	–	2/3	+	+	10/14
Sleep disturbance	8/18	+	2/3	+	–	7/12
Strabismus	8/18	–	2/4	–	+	6/14
Autistic features	4/14	+	0/3	?	–	7/12
Seizures	3/18	+	2/3	Severe	–	3/14

+, present; –, absent; ?, too young to evaluate; NA, unknown

previously shown, DHX30-WT acts as an RNA-dependent ATPase, and its ATPase activity is strongly stimulated by the addition of RNA [8]. In contrast, and similar to the previously analyzed mutants [8] all missense variants (p.(Gly462-Glu), p.(Arg725His), p.(Ala734Asp), p.(Ser737Phe), p.(Thr739Ala), p.(Arg782Gln), and p.(Arg908Gln)) show a significant reduction in ATPase activity in the presence of exogenous RNA (Fig. 2a). For control experiments, we included two common non-synonymous *DHX30* variants found in public repositories [35]. Namely, p.(Val556Ile) is located within the helicase core region albeit not within a HCM, similar to p.(Arg725His), and p.(Glu948Lys) in the vicinity of p.(Arg908Gln). Notably, in comparison to the missense variants identified in affected individuals, the ATPase activity was not significantly reduced neither for p.(Val556Ile) nor for p.(Glu948Lys) (Fig. 2b).

RNA helicase activity of DHX30 is disrupted by missense variants within the helicase core motifs

DHX30 has been classified as an RH due to the presence of the highly conserved motifs in its helicase core region and sequence similarity to other RHs. To confirm that it indeed possesses RNA helicase activity we established an RNA unwinding assay for recombinant full-length DHX30 purified from bacteria as a His₆-SUMO-tagged protein. As a substrate, we used a synthetic [³²P]-labeled RNA molecule which carries a sequence with a strong propensity to self-anneal and form a double helix. Analysis of this RNA substrate by non-denaturing PAGE resulted in a single band of low electrophoretic mobility, corresponding to the dimer linked by the double helical segment. This dimer could be resolved into a band of higher mobility, the monomer, by pre-incubation at 96 °C (Fig. 2c). To identify the amount of the DHX30-WT necessary to resolve the dimeric form we performed a titration analysis from 1 to 160 ng. In the presence of ATP, 10 ng of DHX30-WT was sufficient to resolve the dimer into the monomeric form, confirming that DHX30 indeed possesses the ATP-dependent RNA helicase activity (Fig. 2c and Additional file 7: Figure S4). We next analyzed the impact of selected missense variants on the helicase activity, each affecting a different helicase core motif (p.(Gly462Glu) in motif I, p.(Arg493His) in motif Ia, p.(His562Arg) in motif II, p.(Ser737Phe) in motif V, and p.(Arg785Cys) in motif VI) along with p.(Arg908Gln) located in the RL domain. All missense variants within a HCM failed to unwind the RNA substrates in this assay, whereas the p.(Arg908Gln) mutant behaved similarly to DHX30-WT (Fig. 2d). It is worth noting that we subsequently failed to purify the p.(Arg725His) mutant protein product. This finding suggests misfolding of this mutant protein, followed by either deposition of the insoluble protein in

inclusion bodies or its direct degradation [38]. Thus, we could not analyze its impact on the helicase activity.

Subcellular localization and effect on global translation of novel DHX30 missense variants

We have previously shown that the expression of mutant forms of DHX30 induces the formation of stress granules, concomitant with a global down-regulation of translation [8]. Therefore, we repeated this analyses for selected novel missense variants. In keeping with the previous results [8], we observed that mutants within a HCM, p.(Gly462Glu), p.(Ala734Asp), p.(Ser737Phe), and p.(Thr739Ala), also strongly accumulated in cytoplasmic foci shown to be stress granules upon co-staining with Ataxin-2 (ATXN2). Expression of the p.(Arg908Gln) mutant, however, resulted in localization to cytoplasmic aggregates that co-stained with Ataxin-2 in only 50% of the transfected cells. In contrast, p.(Arg725His) was mostly diffusely localized throughout the cytoplasm similar to the DHX30-WT (Fig. 3 and Additional file 8: Figure S5). Global translation was measured by incorporation of puromycin into nascent peptide chains, which were visualized with a puromycin-specific antibody. Interestingly, expression of both the HCM mutants and the p.(Arg908Gln) mutant resulted in dramatically decreased puromycin incorporation, suggestive of a global decrease in protein synthesis (Fig. 3). Analogous to the results obtained in the ATPase assay, the two common variants p.(Val556Ile) and p.(Glu948Lys) were diffusely localized throughout the cytoplasm, resembling the DHX30-WT (Additional file 8: Figure S5).

In vivo analyses of selected DHX30 missense variants

Given the somewhat conflicting results of functional analyses of the p.(Arg725His) and p.(Arg908Gln) variants, and in order to gain a better understanding of the impact of *DHX30* missense variants in vivo, we utilized a zebrafish model. Previous studies showed that overexpression of pathogenic alleles in zebrafish results in defective embryonic development [39, 40]. Thus, we overexpressed human wild-type DHX30 cDNA or DHX30 cDNA harboring selected missense variants, p.(Arg493His), p.(Arg725His), p.(Arg785Cys), and p.(Arg908Gln) as well as p.(Val556Ile) and p.(Glu948Lys) in zebrafish using Tol2 transposition. Tol2 mRNA and pTol2pA2-cmlc2:EGFP;tuba1a:DHX30 were co-injected into 1-cell stage zebrafish embryos. For analyses, we selected embryos with strong cmlc2:EGFP expression which indicates a high level of transgene integration in somatic cells. Overexpression of DHX30-WT, p.(Val556Ile) or p.(Glu948Lys) had little or no impact on zebrafish embryonic development: over 88% of embryos displayed normal development and morphology. However, expression of DHX30 harboring one of the missense variants resulted in developmental defects in 75–90% of embryos (Fig. 4 and Additional file 9: Figure S6),





Fig. 2 Protein variants of *DHX30* affect ATPase and helicase activity. **a, b** ATPase assays were performed for *DHX30*-WT, novel *DHX30* missense variants (**a**), and two common polymorphisms, p.(Val556Ile) and p.(Glu948Lys) (**b**) in the presence of exogenous RNA. ATPase activity was calculated by subtracting phosphate values obtained with GFP alone from those obtained with GFP-tagged *DHX30*-WT and mutants. These figures were then normalized on precipitated protein amounts using the intensities of the GFP signal in the western blot. Means \pm standard deviation values are based on 3 replications. ****: significantly different from *DHX30*-WT, ns: not significantly different from *DHX30*-WT (** $p < 0.01$; *** $p < 0.001$; $n = 3$; One-Way ANOVA, followed by Dunnett's multiple comparisons test). Values were normalized on *DHX30*-WT ATPase activity obtained in the presence of RNA. **c** Increasing amounts of His₆-SUMO-tagged *DHX30* WT protein were incubated with a ³²P-labeled RNA substrate in the presence (lane 3–7) or absence (lane 8) of ATP and analyzed by native PAGE. The position of the RNA duplex and the single-stranded RNA are indicated in the first and second lanes, respectively. Their schematic representation is shown at the right side. **d** Helicase assay was repeated for selected *DHX30* missense variants affecting either conserved motifs within the helicase core region (lane 4–8) or the auxiliary RL domain (lane 9)

suggesting that these mutant alleles interfere with normal embryonic development and supporting the pathogenicity of p.(Arg725His) and p.(Arg908Gln).

Analyses of the nature of the *DHX30* missense variants


Given the somewhat milder clinical presentation of individuals carrying a whole gene deletion, in-frame deletion, frameshift, or nonsense variant as compared to the individuals harboring a *de novo* missense variant in one of the

HCMs, we further investigated the nature of the latter. First, we analyzed the localization of the RFP-tagged *DHX30*-WT co-expressed with respective GFP-tagged missense variants. Notably, their equimolar expression resulted in each case in *DHX30*-WT being localized in Ataxin-2 positive cytoplasmic clusters (Fig. 5). These data suggest that these missense variants either exert a dominant negative effect on the wild-type or lead to a gain-of-function since both overexpressed *DHX30*-WT and



endogenous *DHX30* are recruited to cytoplasmic clusters only after stress [8].

Next, we analyzed if the *DHX30*-WT can rescue the inability of p.(Arg493His), p.(His562Arg), and p.(Arg785Cys) to unwind RNA. The addition of *DHX30*-WT to p.(His562Arg) and p.(Arg785Cys) efficiently resolved the dimer into the monomeric form even in the presence of increased amounts of the respective mutants. However, we observed only a partial rescue when *DHX30*-WT was added to the p.(Arg493His) variant (Fig. 6a). Our data suggest that the mutants cause a loss of helicase function rather than having a dominant negative effect. Given these somewhat contradictory results, we turned again to the zebrafish model. We co-injected pTol2pA2-cmlc2:EGFP;tuba1a:*DHX30* p.(Arg493His) or p.(Arg785Cys) with wild-type *DHX30* cDNA and assessed embryonic development. Interestingly, co-injection of *DHX30*-WT, at a similar level, partially




rescued the abnormal phenotypes associated with both p.(Arg493His) and p.(Arg785Cys) (Fig. 6b), a finding that could potentially support both loss-of-function and a dominant negative effect as a mechanism underlying disease.

DHX30 deficiency impairs stress granules formation in HEK293T cells and zebrafish

To further characterize the role of *DHX30* we established HEK293T *DHX30* stable knockout lines. CRISPR/Cas9 based knockout (KO) of *DHX30* in HEK293T cells yielded several cell lines with a residual *DHX30* immunoreactivity of less than 10 % (Fig. 7). Given that *DHX30* is recruited to SGs, we wondered whether *DHX30* additionally plays a role in SG formation. Therefore, we assessed the ability of KO cells to induce SGs or cytoplasmic clusters following heat stress treatment. By incubating cells at 43.5 °C, a condition after which endogenous *DHX30* accumulates in SGs [8], we observed that KO cells had a significantly reduced number of SG-positive cells as compared to HEK293T WT cells (Fig. 7). These data suggest a previously unknown role of *DHX30* in SG assembly. Combined with our previous findings (Fig. 3 and 5) these data actually suggest that the HCM missense variants exhibit a gain of function by triggering SG formation which results in global translation inhibition.

Next, we generated a predicted null allele in the single zebrafish *dhx30* ortholog using CRISPR/Cas9. At day five post fertilization, transcript levels of *dhx30* were barely detectable in homozygous mutant animals compared to wild-type, whereas heterozygous siblings



displayed $\sim 30\%$ lower *dhx30* expression as compared to wild type, potentially due to nonsense mediated decay of the mutated alleles (Additional file 10: Figure S7). The homozygous mutant animals are viable, fertile, and morphologically indistinguishable from their wild-type and heterozygous siblings (data not shown). Previous studies have demonstrated that during early embryonic development, zebrafish exhibit robust SG formation in response to stress, such as heat shock [41]. Therefore, based on our *in vitro* findings, we first asked whether *dhx30* mutant zebrafish also exhibit impaired SG formation *in vivo*. At 24-h post-fertilization and normal condition, compared to *dhx30*-WT the homozygous mutant exhibited significantly lower number of SGs, determined by

staining for TIAL-1, an established stress granule marker (Fig. 8). Although an increase in SG formation occurred upon heat shock, the number of TIAL-1-labeled SGs remained significantly lower in the homozygous mutants compared to sibling controls (Fig. 8). Thus, these data show that SG formation is compromised in the homozygous mutants and suggests an evolutionarily conserved role for DHX30 in SG assembly.

Dhx30-deficient zebrafish display altered behavioral activity

We next examined whether *dhx30*-deficient zebrafish exhibit abnormal sleep-wake activity and social behaviors, similar to those recently observed in a zebrafish




Fig. 6 Analyses of the nature of missense variants within the helicase core motifs (HCM). **a** RNA unwinding activity of purified DHX30 R493H, H562R, and R785C mutants was analyzed upon addition of DHX30 WT protein. Increasing amounts of mutant proteins were incubated with 20 ng of WT protein and assayed for their ability to unwind a radiolabeled RNA duplex in the presence of ATP. **b** Assessment of embryonic development after co-injection of DHX30 R493H and R785C with DHX30 WT cDNA in a zebrafish model. Bar graph indicating the percentage of *cmc12*-GFP positive zebrafish embryos 4–7 days postfertilization (dpf). The presented data are derived from three independent studies. The total number of embryos assessed are 58, 43, and 51 for WT, R493H+WT, and R785C+WT, respectively. ****: significantly different from WT (**** $p < 0.0001$; χ^2 test)

model of the NR3C2-related neurodevelopmental disorder [25]. We first analyzed sleep-wake behaviors in 5-day-old *dhx30* KO mutants. Compared to wild-type and heterozygous siblings, the homozygous mutants displayed significantly less activity during the day and more nocturnal activity (Fig. 9a–c), mimicking somewhat the sleep disturbances in individuals affected by a *DHX30*-related neurodevelopmental disorder. Additionally, using an established social preference assay, we observed that the wild-type and heterozygous animals showed the previously described social behavior of preferring to stay close to conspecific fish of similar age and size, whereas the homozygous animals did not show this preference (Fig. 9d–e). There were no obvious dysmorphic phenotypes in the homozygous mutant animals compared to their wild-type and heterozygous siblings. We propose, therefore, that the mutant phenotype was not simply due to developmental delay but influenced by abnormalities in complex neural circuitry. Taken together, our data indicate that *dhx30* KO zebrafish have a social behavioral deficit with altered sleep-wake activity, which is

consistent with findings in *DHX30*-related neurodevelopmental disorders.

Discussion

Our study has allowed further delineation of the clinical spectrum of *DHX30*-related neurodevelopmental disorders through analysis of 25 novel affected individuals, partially facilitated by the use of a social media-based family support group. Individuals harboring heterozygous missense variants affecting highly conserved residues within a HCM present with global developmental delay, intellectual disability, muscular hypotonia, severe gait abnormalities (if walking is acquired), and remain non-verbal or speak only single words. We also identified microcephaly as an additional common feature. Individuals with either a mosaic missense variant within a HCM, or with variants resulting in haploinsufficiency or with protein-truncating variants all learned to walk in the second year of life, had a mild muscular hypotonia, and spoke at least 20 words by the age of 3 years. Therefore, based on the clinical and molecular findings we




Fig. 7 *DHX30* deficiency in HEK293T cells leads to reduced formation of stress granules. **a** Immunocytochemical detection of endogenous ATXN2 (magenta) in WT HEK293T cells and *DHX30*-deficient HEK293T cells before (left panel) and after (right panel) heat shock at 43.5 °C for 1 h. Note that, upon heat stress and depletion of *DHX30* (right hand, lower panel), ATXN2 does not alter its diffuse cytoplasmic distribution to accumulate in cytoplasmic foci, as observed in WT HEK293T cells (right hand, upper panel). Nuclei are identified via DAPI staining (blue). Scale bars indicate 10 μ m. **b** Bar graph indicating the percentage of cells containing stress granules. (*: significantly different from WT HEK293T cells: * $p < 0.05$; $n > 200$ from 3 independent experiments; unpaired t test). **c** Western blotting detection of *DHX30* knock-out efficiency in HEK293T cells. Expression of *DHX30* was reduced by 90% as detected by a *DHX30* specific antibody. Tubulin was used as loading control


suggest a classification in two *DHX30*-associated neurodevelopmental disorder subtypes.

It is worth noting that the identified heterozygous deletion in individual 24 also encompasses the first 15 *SETD2* exons, suggestive of a dual diagnosis. However, given the phenotypic differences in the seven individuals reported to date, some of whom inherited their *SETD2* variant from an apparently unaffected parent [32–34], we are unsure to what extent loss of *SETD2* contributed to the phenotype observed in this individual.

Identification of affected individuals with milder phenotype challenges naming of this disorder “Neurodevelopmental disorder with severe motor impairment and absent language” (NEDMIAL; OMIM # 617804). Notably, only 9 of the 25 individuals (36%) presented here had a severe motor impairment (never learned to walk) and 9 out of 25 individuals (36%) spoke at least single


words, thus did not have a completely absent language. Therefore, we suggest referring to these conditions as *DHX30*-associated neurodevelopmental disorders in the future.

To provide further evidence for the pathogenicity of the novel *DHX30* variants and gain better insight into the genotype-phenotype correlation we performed several in vitro and in vivo analyses. For this, we have now formally confirmed that *DHX30* possesses ATP-dependent RNA helicase activity. In line with their absence from public databases and high evolutionary conservation of affected amino acid residues, all novel missense variants within a HCM resulted in impaired ATPase activity (all were within an ATP binding and hydrolysis motif), impaired helicase activity, and showed an increased propensity to trigger stress granule (SG) formation resulting in inhibition of global translation, as expected from the previous study [8]. In addition,



selected HCM missense variants interfere with normal zebrafish embryonic development.

We have previously suggested that the missense variants within HCM might have a more severe effect than a loss of one gene copy [8]. This hypothesis is now supported by identification of four affected individuals carrying variants that result in either haploinsufficiency or a truncated protein, all of whom presented with a milder phenotype as compared to the individuals harboring missense variants within HCM. To gain further insight into the nature of these variants we determined that *DHX30*-WT can rescue the inability of selected HCM missense variants to unwind an RNA duplex, and that co-injection of *DHX30*-WT with selected HCM missense variants can partially ameliorate the observed zebrafish phenotypes. These data point to loss-of-function effects of the HCM mutants on a molecular level. However, co-expression of HCM missense variants together



with the DHX30-WT resulted in recruitment of DHX30-WT into SG's, a finding that might possibly suggest a dominant negative effect. It is worth noting that DHX30-WT, as well as the endogenous protein, are recruited to the SG's after stress induction [8]. Thus, HCM missense variants might actually result in a detrimental gain-of-function by inducing SG formation with concomitant global translation impairment even without endogenous or exogenous stressors.

To gain further clarity we focused on the relation of DHX30 to SG formation. Using CRISPR/Cas9 based technology, we established two *DHX30* knockout models. Analyses of both, *DHX30*-deficient HEK293T cells and zebrafish, revealed an impairment of SG formation upon heat stress, pointing to an essential and evolutionary conserved role of DHX30 in SG assembly. These findings provide a molecular explanation for the above-mentioned phenotypic differences, as they strongly suggest that pathogenic missense HCM variants, in addition to the loss of ATPase or RNA-binding activity and with impaired helicase function, exert a selective gain-of-function by triggering SG formation. This is in line with our hypothesis that due to SG hyper-assembly these pathogenic variants generate a chronic condition of impaired translation [8]. Noteworthy, impaired translation due to aberrant SG formation is associated with a broad variety of neurodegenerative and neurodevelopmental diseases [8, 42]. Furthermore, repeat expansion underlying *C9orf72*-associated neurodegenerative disorders has recently been suggested to result in chronic cellular stress due to aberrant SG formation [43].

Beyond providing the molecular explanation for the genotype-phenotype correlation of these two subtypes we additionally performed in vivo behavioral modeling of zebrafish *dhx30* KO's. Zebrafish exhibit all the hallmarks of mammalian sleep by utilizing neurotransmitters known to coordinate sleep and wake states in humans [44]. Analysis of *dhx30*-deficient animals revealed a compromised sleep/wake behavior, as they were less active during the day but more active and slept less at night than *dhx30*-WT animals. This is partially reminiscent of the sleep disturbances observed in almost half of DHX30-affected individuals. Additionally, homozygous *dhx30* KO animals displayed altered social behavior as manifested by their performance in the social preference assay, e.g., showing reduced preference for conspecifics as compared to *dhx30*-WT zebrafish. The observed social behavioral deficits and altered sleep-wake activity are similar to the findings in zebrafish models of other neurodevelopmental disorders [25, 45], and to some extent recapitulate the clinical findings in individuals affected by the *DHX30*-related neurodevelopmental disorder.

Furthermore, we present here two individuals who clearly stand out both in terms of their clinical presentation and their identified *DHX30* variant. Individual 4 with an early-lethal infantile epileptic encephalopathy carries a homozygous missense variant, p.(Arg725His), and individual 21 with a de novo p.(Arg908Gln) variant shows late-onset progressive ataxia. Trio-WES analysis performed in both individuals identified these *DHX30* variants as the only candidates (Supplementary Data). As

Table 2 Summary of functional analyses of missense variants

<i>DHX30</i> variant	p.(Gly462Glu), p.(His562Arg), p.(Ala734Asp), p.(Ser737Phe), p.(Thr739Ala), p.(Gly781Asp), p.(Arg782Gln), p.(Arg782Trp), p.(Arg785Cys), p.(Arg785His)	p.(Arg493His)	p.(Arg725His)	p.(Arg908Gln)	p.(Val556Ile)	p.(Glu948Lys)
Location in DHX30	Helicase core motifs I, II, V, or VI (nucleotide-interacting motifs)	Helicase core motif Ia (nucleic acid-binding)	Helicase core region, between motifs IV and V	Ratchet-like domain	Helicase core region, between motifs Ib and II	C-terminal region
gnomAD v2.1.1	Not identified	Not identified	Not identified	Not identified	0/39/282352	1/49/282090
ATPase activity	Reduced	Similar to wt*	Reduced	Reduced	Similar to wt	Similar to wt
RNA binding capacity	n.d.	Reduced*	n.d.	n.d.	n.d.	n.d.
Helicase activity	Reduced**	Reduced	n.d.***	Similar to wt	n.d.	n.d.
Cellular localization	Stress granules	Stress granules	Cytoplasmic, similar to wt	Cytoplasmic aggregates	Cytoplasmic, similar to wt	Cytoplasmic, similar to wt
Puromycin incorporation	Impaired	Impaired*	Similar to wt	Impaired	n.d.	n.d.
Zebrafish development	Impaired**	Impaired	Impaired	Impaired	Similar to wt	Similar to wt

n.d., not determined; *, Lessel et al. 2017; **, only selected variants analyzed; ***, unable to purify the protein

these variants occurred outside the HCM motifs, we included two similarly located common non-synonymous *DHX30* variants found in gnomAD, p.(Val556Ile) and p.(Glu948Lys), in our functional analysis for comparison. However, these two latter variants behaved similarly to *DHX30*-WT in all assays performed (Table 2).

For the variant p.(Arg725His), located within the helicase core region but not within a HCM, we observed a reduced ATPase activity. However, unlike HCM missense variants it does not trigger SG hyper-assembly. When attempting to analyze its impact on the helicase activity we consistently failed to purify the p.(Arg725His) mutant protein product. We therefore suggest that this biallelic variant leads to a loss-of-function, likely due to misfolding. The fact that it was inherited from unaffected heterozygous parents indicates that its effect is somewhat milder as compared to the variants identified here resulting in haploinsufficiency or protein-truncation, and that similar heterozygous missense variants may not contribute to disease.

The de novo missense variant p.(Arg908Gln) affects a highly conserved residue within the RL domain. This variant impairs the ATPase but not helicase activity of *DHX30*, suggesting that the RL domain is required for the coupling of helicase activity to ATP hydrolysis. Whereas this variant leads to formation of aberrant cytoplasmic aggregates, which cannot be eliminated by co-expression of *DHX30*-WT, not all of these aggregates/foci could be confirmed to be translationally silent SGs.

The functional characterization of both variants identified differences to HCM missense variants, which may potentially explain the genotype-phenotype correlation. Additionally, both individuals presented with clinical signs and symptoms observed in other affected individuals, suggestive of a phenotypic continuum. We cannot exclude, however, the possibility that they carry additional variants with phenotypic consequences, which were undetected by trio-whole exome sequencing. Identification of similarly affected individuals carrying similar variants is required to establish their causality.

Conclusions

The identification of 25 affected individuals has expanded the clinical and genetic spectrum of the *DHX30*-associated neurodevelopmental disorder. Our data suggest the existence of clinically distinct subtypes correlating with location and nature of pathogenic variants. Our study highlights the usefulness of social media-based family support groups as a resource in defining ultra-rare disorders as well as the need for *in-depth* functional characterization of potentially pathogenic variants to understand their biological consequences. We confirmed that *DHX30* is an ATP-dependent RNA helicase, and showed that *DHX30* is essential for stress granule

assembly in cellular and *in vivo* models. Missense variants in helicase core motifs lead to a loss of ATPase and helicase activity, concomitant with a gain-of-function with respect to SG formation, and a severe phenotype. In contrast, *DHX30* loss-of-function variants are associated with a milder phenotype. Additional studies are required to further delineate the variety of clinical outcomes underlying different *DHX30* variants as well as the roles of *DHX30* in various aspects of RNA metabolism.

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s13073-021-00900-3>.

Additional file 1. Supplementary methods.

Additional file 2: Table S1. Summary on clinical features of individuals bearing pathogenic *DHX30* variants.

Additional file 3: Figure S1. Identified missense variants affect highly conserved amino acids.

Additional file 4: Figure S2. *De novo* mosaicism in individual 6.

Additional file 5: Figure S3. Whole gene deletion in individual 24.

Additional file 6. Clinical reports of here presented individuals.

Additional file 7: Figure S4. *DHX30* WT acts as an ATP-dependent RNA helicase.

Additional file 8: Figure S5. Recombinant protein variants of *DHX30* induce the formation of cytoplasmic clusters.

Additional file 9: Figure S6. Representative images of zebrafish embryos.

Additional file 10: Figure S7. Generation of zebrafish CRISPR-Cas9-mediated *dhx30* stable knockout line.

Acknowledgements

We thank all affected individuals and their family members/legal guardians for their participation and collaboration, Hans-Hinrich Hönck (Institute for Human Genetics, UKE Hamburg) for technical assistance, and UKE microscopic imaging facility (umif) for providing assistance with confocal microscopes.

Authors' contributions

I.M., N.D.P.D., H.H., J.W., J.M.P., U.F., N.C.Y., H-J.K., and D.L. generated and analyzed the functional data. Zebrafish experiments were designed and performed in the laboratory of N.C.Y. D.L. and H-J.K. supervised the study. D.L. wrote the manuscript. J.B.M., J.A., T.A., S.B., G.B., D.B., A.B., P.J.B., S.B., T.B., F.B., L.A.B., G.J.B., Ø.L.B., J.C., J.D., L.F.E., C.E., J.F., D.G., C.A.H., M.H., Y.H-M., G.H., A.J., L.K., B.K., C.K-B., C.Kr., C.Ku., G.L.G., U.W.L., L.M.B., J.A.M-A., M.M., D.T.M., Q.Q.M., B.M., C.N., S.F.N., T.P., F.R., H.R., S.F.R., J.S-H., P.B.S., A.S., S.S., A.P.A.S., K.To., K.Tv., J.H.W., C.Z., K.M., J.J., and F.Q-R. identified and collected affected individuals. All authors read and approved the final manuscript.

Funding

This work was funded in part by Werner Otto Stiftung (to D.L. and H-J.K.) and Deutsche Forschungsgemeinschaft (LE4223/1-1 to D.L.; Kr1321/9-1 to H-J.K.) by startup funds from University of Alabama, Birmingham (to N.C.Y.), by NIH U54 OD030167 (to J.P.M.), by the UCLA Pathology Translational Research Fund (to J.B.M. and F.Q-R.) and by the UCLA California Center for Rare Diseases (to S.F.N.). Open Access funding enabled and organized by Projekt DEAL.

Availability of data and materials

The raw next-generation sequencing and microarray-based comparative genomic hybridization data that support the findings in affected individuals cannot be made publicly available for reasons of patient confidentiality. Qualified researchers may apply for access to these data, pending

institutional review board approval (contact D.L., d.lesse@uke.de). Cells (contact H.-J.K., kreienkamp@uke.de) and zebrafish (contact N.C.Y., nyeo@uab.edu) are available upon signing a material transfer agreement. All other data generated or analyzed during this study are included in the main text and/or the additional files.

The newly identified *DHX30* variants have been deposited to the Leiden Open (source) Variation Database (LOVD) [46] (<https://databases.lovd.nl/shared/variants/DHX30/unique>) with the following variant numbers #0000763353 to #0000763362:

<https://databases.lovd.nl/shared/variants/0000763353> [47]
<https://databases.lovd.nl/shared/variants/0000763354> [48]
<https://databases.lovd.nl/shared/variants/0000763355> [49]
<https://databases.lovd.nl/shared/variants/0000763356> [50]
<https://databases.lovd.nl/shared/variants/0000763357> [51]
<https://databases.lovd.nl/shared/variants/0000763358> [52]
<https://databases.lovd.nl/shared/variants/0000763359> [53]
<https://databases.lovd.nl/shared/variants/0000763360> [54]
<https://databases.lovd.nl/shared/variants/0000763361> [55]
<https://databases.lovd.nl/shared/variants/0000763362> [56]

Declarations

Ethics approval and consent to participate

The study was performed in accordance with the Declaration of Helsinki protocols. Written informed consent for all 25 subjects was obtained from the parents or legal guardians in accordance with protocols approved by the Ethics Committee of the Hamburg Chamber of Physicians: PV 3802 and the University of California, Los Angeles (UCLA) IRB: 11-001087. Zebrafish were maintained according to protocols by the University of Alabama Zebrafish Research Facility (ZRF) Animal Resources Program which maintains full Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC) accreditation and is assured with the Office of Laboratory Animal Welfare (OLAW). All zebrafish studies followed protocols approved by the University of Alabama Institutional Animal Care and Use Committee (IACUC): APN22158.

Consent for publication

A written consent was obtained from the parents or legal guardians to publish the details of all 25 affected individuals.

Competing interests

K.M. and J.J. are employees of GeneDx, Inc. The remaining authors declare that they have no competing interests.

Author details

¹Institute of Human Genetics, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany. ²Department of Pharmacology and Toxicology, University of Alabama, Birmingham, USA. ³Department of Biochemistry, Theodor Boveri Institute, Biocenter of the University of Würzburg, 97070 Würzburg, Germany. ⁴Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA. ⁵UCLA Clinical Genomics Center, University of California Los Angeles, Los Angeles, CA, USA. ⁶Department of Physiology, University of California Los Angeles, Los Angeles, CA, USA. ⁷Manchester Centre for Genomic Medicine, St Mary's Hospital, Manchester University NHS Foundation Trust, Health Innovation Manchester, Manchester, UK. ⁸Division of Evolution & Genomic Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK. ⁹Faculty of Medicine and Health Sciences, University of Western Australia, Perth, WA, Australia. ¹⁰Western Australian Register of Developmental Anomalies, King Edward Memorial Hospital, Perth, Australia. ¹¹Telethon Kids Institute, Perth, Australia. ¹²Division of Child Neurology, Department of Neurology, University of Rochester School of Medicine, Rochester, NY, USA. ¹³Clinical Genetics Department, University Hospitals Bristol and Weston, Bristol, UK. ¹⁴Joe DiMaggio Children's Hospital, Hollywood, FL, USA. ¹⁵Department of Medical Genetics, Haukeland University Hospital, 5021 Bergen, Norway. ¹⁶Department of Medical Genetics, Centre Hospitalier Universitaire de Poitiers, Poitiers, France. ¹⁷Laboratoire de Neurosciences Cliniques et Expérimentales-INSERM U1084, Université de Poitiers, Poitiers, France. ¹⁸Department of Clinical Medicine (K1), University of Bergen, Bergen, Norway. ¹⁹Department of Neurology, Haukeland University Hospital, Bergen,

Norway. ²⁰Department of Medical Genetics, Telemark Hospital Trust, Skien, Norway. ²¹Division of Medical Genetics, Department of Pediatrics, University of California San Francisco, San Francisco, CA, USA. ²²Department of Pediatrics, University Medical Center Eppendorf, 20246 Hamburg, Germany. ²³Peyton Manning Children's Hospital, Ascension Health, Indianapolis, IN, USA. ²⁴Department of Pediatrics, Southern Illinois University School of Medicine, Springfield, IL 62702, USA. ²⁵Department of Pediatric Neurology, Amalia Children's Hospital and Donders Institute for Brain, Cognition and Behavior, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands. ²⁶Division of Neurology, Department of Pediatrics, Ann and Robert H. Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. ²⁷Kaiser Permanente Sacramento, Sacramento, USA. ²⁸Département de Génétique, Hôpital La Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Paris, France. ²⁹Genetic Services of Western Australia, Perth, Western Australia 6008, Australia. ³⁰Institute of Human Genetics, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Germany. ³¹Department of Pediatrics, Vestfold Hospital, 3116 Tønsberg, Norway. ³²Department of Genetics, Kaiser Permanente Northern California, Oakland, USA. ³³Semel Institute of Neuroscience and Human Behavior, University of California Los Angeles, Los Angeles, CA, USA. ³⁴Department of Pediatrics, Division of Medical Genetics at David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA. ³⁵Department of Human Genetics at David Geffen School of Medicine University of California Los Angeles, Los Angeles, CA, USA. ³⁶Department of Medicine, Hugh Kaul Precision Medicine Institute, University of Alabama at Birmingham, 510 20th St S, Birmingham, AL 35210, USA. ³⁷Division of Genetics and Genomics, Boston Children's Hospital, Boston, MA, USA. ³⁸Center for Duchenne Muscular Dystrophy, University of California Los Angeles, Los Angeles, CA, USA. ³⁹UF de Génétique Médicale, GHRS, CHU de La Réunion, Saint Pierre, La Réunion, France. ⁴⁰Department of Human Genetics, Radboud University Medical Center, 6500 HB Nijmegen, the Netherlands. ⁴¹Department of Neurology at David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA. ⁴²Department of Clinical Genetics, Maastricht University Medical Center, Maastricht, The Netherlands. ⁴³Department of Neurology, Boston Children's Hospital, Boston, MA, USA. ⁴⁴Department of Human Genetics, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland. ⁴⁵GeneDx, Gaithersburg, MD 20877, USA. ⁴⁶Department of Pathology and Laboratory Medicine, School of Medicine, University of California Irvine, Irvine, CA, USA.

Received: 2 September 2020 Accepted: 28 April 2021

Published online: 21 May 2021

References

- Jankowsky E. RNA helicases at work: binding and rearranging. *Trends Biochem Sci.* 2011;36(1):19–29. <https://doi.org/10.1016/j.tibs.2010.07.008>.
- Linder P, Jankowsky E. From unwinding to clamping - the DEAD box RNA helicase family. *Nat Rev Mol Cell Biol.* 2011;12(8):505–16. <https://doi.org/10.1038/nrm3154>.
- Umate P, Tuteja N, Tuteja R. Genome-wide comprehensive analysis of human helicases. *Commun Integr Biol.* 2011;4(1):118–37. <https://doi.org/10.4161/cib.13844>.
- Heerma van Voss MR, van Diest PJ, Raman V. Targeting RNA helicases in cancer: The translation trap. *Biochim Biophys Acta Rev Cancer.* 2017;1868(2): 510–20. <https://doi.org/10.1016/j.bbcan.2017.09.006>.
- Cai W, Xiong Chen Z, Rane G, Satendra Singh S, Choo Z, Wang C, et al. Wanted DEAD/H or Alive: Helicases Winding Up in Cancers. *J Natl Cancer Inst.* 2017;109(6):djw278. <https://doi.org/10.1093/jnci/djw278>.
- Snijders Blok L, Madsen E, Juusola J, Gilissen C, Baralle D, Reijnders MR, et al. Mutations in *DDX3X* Are a Common Cause of Unexplained Intellectual Disability with Gender-Specific Effects on Wnt Signaling. *Am J Hum Genet.* 2015;97(2):343–52. <https://doi.org/10.1016/j.ajhg.2015.07.004>.
- Balak C, Benard M, Schaefer E, Iqbal S, Ramsey K, Ernoult-Lange M, et al. Rare De Novo Missense Variants in RNA Helicase *DDX6* Cause Intellectual Disability and Dysmorphic Features and Lead to P-Body Defects and RNA Dysregulation. *Am J Hum Genet.* 2019;105(3):509–25. <https://doi.org/10.1016/j.ajhg.2019.07.010>.
- Lesse D, Schob C, Kury S, Reijnders MRF, Harel T, Eldomery MK, et al. De Novo Missense Mutations in *DHX30* Impair Global Translation and Cause a Neurodevelopmental Disorder. *Am J Hum Genet.* 2017;101(5):716–24. <https://doi.org/10.1016/j.ajhg.2017.09.014>.

9. Shamseldin HE, Rajab A, Alhashem A, Shaheen R, Al-Shidi T, Alamro R, et al. Mutations in DDX59 implicate RNA helicase in the pathogenesis of orofaciocigital syndrome. *Am J Hum Genet.* 2013;93(3):555–60. <https://doi.org/10.1016/j.ajhg.2013.07.012>.
10. Paine I, Posey JE, Grochowski CM, Jhangiani SN, Rosenheck S, Kleyner R, et al. Paralog Studies Augment Gene Discovery: DDX and DHX Genes. *Am J Hum Genet.* 2019;105(2):302–16. <https://doi.org/10.1016/j.ajhg.2019.06.001>.
11. Cross LA, McWalter K, Keller-Ramey J, Henderson LB, Amudhavalli SM. A report of gonadal mosaicism in DHX30-related neurodevelopmental disorder. *Clin Dysmorphol.* 2020;29(3):161–4. <https://doi.org/10.1097/MCD.0000000000000316>.
12. Lessel D, Zeitler DM, Reijnders MRF, Kazantsev A, Hassani Nia F, Bartholomaeus A, et al. Germline AGO2 mutations impair RNA interference and human neurological development. *Nat Commun.* 2020;11(1):5797. <https://doi.org/10.1038/s41467-020-19572-5>.
13. Lee H, Deignan JL, Dorrani N, Strom SP, Kantarci S, Quintero-Rivera F, et al. Clinical exome sequencing for genetic identification of rare Mendelian disorders. *JAMA.* 2014;312(18):1880–7. <https://doi.org/10.1001/jama.2014.14604>.
14. Lessel D, Gehbauer C, Bramswig NC, Schluth-Bolard C, Venkataramanappa S, van Gassen KLI, et al. BCL11B mutations in patients affected by a neurodevelopmental disorder with reduced type 2 innate lymphoid cells. *Brain.* 2018;141(8):2299–311. <https://doi.org/10.1093/brain/awy173>.
15. Retterer K, Juusola J, Cho MT, Vitazka P, Millan F, Gibellini F, et al. Clinical application of whole-exome sequencing across clinical indications. *Genet Med.* 2016;18(7):696–704. <https://doi.org/10.1038/gim.2015.148>.
16. Deciphering Developmental Disorders S. Prevalence and architecture of de novo mutations in developmental disorders. *Nature.* 2017;542(7642):433–8. <https://doi.org/10.1038/nature21062>.
17. Sadedin SP, Dashnow H, James PA, Bahlo M, Bauer DC, Lonie A, et al. Cppe: a shared variant detection pipeline designed for diagnostic settings. *Genome Med.* 2015;7(1):68. <https://doi.org/10.1186/s13073-015-0191-x>.
18. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet Med.* 2015;17(5):405–24. <https://doi.org/10.1038/gim.2015.30>.
19. Ji J, Lee H, Argiropoulos B, Dorrani N, Mann J, Martinez-Agosto JA, et al. DYRK1A haploinsufficiency causes a new recognizable syndrome with microcephaly, intellectual disability, speech impairment, and distinct facies. *Eur J Hum Genet.* 2015;23(11):1473–81. <https://doi.org/10.1038/ejhg.2015.71>.
20. Kearney HM, Thorland EC, Brown KK, Quintero-Rivera F, South ST, Working Group of the American College of Medical Genetics Laboratory Quality Assurance C. American College of Medical Genetics standards and guidelines for interpretation and reporting of postnatal constitutional copy number variants. *Genet Med.* 2011;13(7):680–5. <https://doi.org/10.1097/GIM.0b013e3182217a3a>.
21. Sobreira N, Schiettecatte F, Boehm C, Valle D, Hamosh A. New tools for Mendelian disease gene identification: PhenoDB variant analysis module; and GeneMatcher, a web-based tool for linking investigators with an interest in the same gene. *Hum Mutat.* 2015;36(4):425–31. <https://doi.org/10.1002/humu.22769>.
22. Guenther UP, Handoko L, Laggerbauer B, Jablonka S, Chari A, Alzheimer M, et al. IGHMBP2 is a ribosome-associated helicase inactive in the neuromuscular disorder distal SMA type 1 (DSMA1). *Hum Mol Genet.* 2009;18(7):1288–300. <https://doi.org/10.1093/hmg/ddp028>.
23. Tseng-Rogenski SS, Chang TH. RNA unwinding assay for DExD/H-box RNA helicases. *Methods Mol Biol.* 2004;257:93–102. <https://doi.org/10.1385/1-59259-750-5:093>.
24. Thomas HR, Percival SM, Yoder BK, Parant JM. High-throughput genome editing and phenotyping facilitated by high resolution melting curve analysis. *PLoS One.* 2014;9(12):e114632. <https://doi.org/10.1371/journal.pone.0114632>.
25. Ruzzo EK, Perez-Cano L, Jung JY, Wang LK, Kashef-Haghighi D, Hartl C, et al. Inherited and De Novo Genetic Risk for Autism Impacts Shared Networks. *Cell.* 2019;178(4):850–66 e826. <https://doi.org/10.1016/j.cell.2019.07.015>.
26. Tanner NK, Linder P. DExD/H box RNA helicases: from generic motors to specific dissociation functions. *Mol Cell.* 2001;8:251–62.
27. Caruthers JM, McKay DB. Helicase structure and mechanism. *Curr Opin Struct Biol.* 2002;12(1):123–33. [https://doi.org/10.1016/S0959-440X\(02\)00298-1](https://doi.org/10.1016/S0959-440X(02)00298-1).
28. Buttner K, Nehring S, Hopfner KP. Structural basis for DNA duplex separation by a superfamily-2 helicase. *Nat Struct Mol Biol.* 2007;14(7):647–52. <https://doi.org/10.1038/nsmb1246>.
29. Tauchert MJ, Fourmann JB, Luhrmann R, Ficner R. Structural insights into the mechanism of the DEAH-box RNA helicase Prp43. *Elife.* 2017;6. <https://doi.org/10.7554/eLife.21510>.
30. Prabu JR, Muller M, Thomae AW, Schussler S, Bonneau F, Becker PB, et al. Structure of the RNA Helicase MLE Reveals the Molecular Mechanisms for Uridine Specificity and RNA-ATP Coupling. *Mol Cell.* 2015;60(3):487–99. <https://doi.org/10.1016/j.molcel.2015.10.011>.
31. Murakami K, Nakano K, Shimizu T, Ohto U. The crystal structure of human DEAH-box RNA helicase 15 reveals a domain organization of the mammalian DEAH/RHA family. *Acta Crystallogr F Struct Biol Commun.* 2017;73(6):347–55. <https://doi.org/10.1107/S2053230X17007336>.
32. Luscan A, Laurendeau I, Malan V, Francannet C, Odent S, Giuliano F, et al. Mutations in SETD2 cause a novel overgrowth condition. *J Med Genet.* 2014;51(8):512–7. <https://doi.org/10.1136/jmedgenet-2014-102402>.
33. Lumish HS, Wynn J, Devinsky O, Chung WK. Brief Report: SETD2 Mutation in a Child with Autism, Intellectual Disabilities and Epilepsy. *J Autism Dev Disord.* 2015;45(11):3764–70. <https://doi.org/10.1007/s10803-015-2484-8>.
34. O’Roak BJ, Vives L, Fu W, Egertson JD, Stanaway IB, Phelps IG, et al. Multiplex targeted sequencing identifies recurrently mutated genes in autism spectrum disorders. *Science.* 2012;338(6114):1619–22. <https://doi.org/10.1126/science.1227764>.
35. Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alfoldi J, Wang Q, et al. The mutational constraint spectrum quantified from variation in 141,456 humans. *Nature.* 2020;581(7809):434–43. <https://doi.org/10.1038/s41586-020-2308-7>.
36. Petrovski S, Wang Q, Heinzen EL, Allen AS, Goldstein DB. Genic intolerance to functional variation and the interpretation of personal genomes. *PLoS Genet.* 2013;9(8):e1003709. <https://doi.org/10.1371/journal.pgen.1003709>.
37. Hempel M, Cremer K, Ockeloen CW, Lichtenbelt KD, Herkert JC, Denecke J, et al. De Novo Mutations in CHAMP1 Cause Intellectual Disability with Severe Speech Impairment. *Am J Hum Genet.* 2015;97(3):493–500. <https://doi.org/10.1016/j.ajhg.2015.08.003>.
38. Baneyx F, Mujacic M. Recombinant protein folding and misfolding in *Escherichia coli*. *Nat Biotechnol.* 2004;22(11):1399–408. <https://doi.org/10.1038/nbt1029>.
39. Davis EE, Frangakis S, Katsanis N. Interpreting human genetic variation with in vivo zebrafish assays. *Biochim Biophys Acta.* 1842;2014:1960–70.
40. Finckbeiner S, Ko PJ, Carrington B, Sood R, Gross K, Dolnick B, et al. Transient knockdown and overexpression reveal a developmental role for the zebrafish *enosf1b* gene. *Cell Biosci.* 2011;1:32.
41. Zampedri C, Tinoco-Cuellar M, Carrillo-Rosas S, Diaz-Tellez A, Ramos-Balderas JL, Pelegrí F, et al. Zebrafish P54 RNA helicases are cytoplasmic granule residents that are required for development and stress resilience. *Biol Open.* 2016;5(10):1473–84. <https://doi.org/10.1242/bio.015826>.
42. Wolozin B, Ivanov P. Stress granules and neurodegeneration. *Nat Rev Neurosci.* 2019;20(11):649–66. <https://doi.org/10.1038/s41583-019-0222-5>.
43. Zhang YJ, Gendron TF, Ebbert MTW, O’Raw AD, Yue M, Jansen-West K, et al. Poly(GR) impairs protein translation and stress granule dynamics in C9orf72-associated frontotemporal dementia and amyotrophic lateral sclerosis. *Nat Med.* 2018;24(8):1136–42. <https://doi.org/10.1038/s41591-018-0071-1>.
44. Sorribes A, Thornorsteinsson H, Arnardottir H, Johannesdottir I, Sigurgeirsson B, de Polavieja GG, et al. The ontogeny of sleep-wake cycles in zebrafish: a comparison to humans. *Front Neural Circuits.* 2013;7:178.
45. Patowary A, Won SY, Oh SJ, Nesbitt RR, Archer M, Nickerson D, et al. Family-based exome sequencing and case-control analysis implicate CEP41 as an ASD gene. *Transl Psychiatry.* 2019;9(1):4. <https://doi.org/10.1038/s41398-018-0343-z>.
46. Fokkema IF, Taschner PE, Schaafsma GC, Celli J, Laros JF, den Dunnen JT. LOVD v2.0: the next generation in gene variant databases. *Hum Mutat.* 2011;32(5):557–63. <https://doi.org/10.1002/humu.21438>.
47. Mannucci I, Dang NDP, Huber H, Murry JB, Abramson J, Althoff T, Banka S, Baynam G, Bearden D, Beleza A, Benke PJ, Berland S, Bierhals T, Bilan F, Bindoff LA, Braathen GJ, L. Busk Ø, Chenbhanich J, Denecke J, Escobar LF, Estes C, Fleischer J, Groepper D, Haaxma CA, Hempel M, Holler-Managan Y, Houge G, Jackson A, Kellogg L, Keren B, Kiraly-Borri C, Kraus C, Kubisch C, Le Guyader G, Ljungblad UW, Brennam LM, Martinez-Agosto JA, Might M, Miller DT, Minks KQ, Moghaddam B, Nava C, Nelson SF, Parant JM, Prescott T, Rajabi F, Randrianaivo H, Reiter SF, Schuurs-Hoeijmakers J, Shieh PB, Slavotinek A, Smithson S, Stegmann APA, Tomczak K, Tveten K, Wang J, Whitlock JH, Zweier C, McWalter K, Juusola J, Quintero-Rivera F, Fischer U, Yeo NC, Kreienkamp H-J, Lessel D. NM_138615.2(DHX30): c.1385G>A (p.

- Gly462Glu). Variant #0000763353. LOVD 3.0. <https://databases.lovd.nl/shared/variants/0000763353>.
48. Mannucci I, Dang NDP, Huber H, Murry JB, Abramson J, Althoff T, Banka S, Baynam G, Bearden D, Beleza A, Benke PJ, Berland S, Bierhals T, Bilan F, Bindoff LA, Braathen GJ, L. Busk Ø, Chenbhanich J, Denecke J, Escobar LF, Estes C, Fleischer J, Groepper D, Haaxma CA, Hempel M, Holler-Managan Y, Houge G, Jackson A, Kellogg L, Keren B, Kiraly-Borri C, Kraus C, Kubisch C, Le Guyader G, Ljungblad UW, Brenman LM, Martinez-Agosto JA, Might M, Miller DT, Minks KQ, Moghaddam B, Nava C, Nelson SF, Parant JM, Prescott T, Rajabi F, Randrianaivo H, Reiter SF, Schuurs-Hoeijmakers J, Shieh PB, Slavotinek A, Smithson S, Stegmann APA, Tomczak K, Tveten K, Wang J, Whitlock JH, Zweier C, McWalter K, Juusola J, Quintero-Rivera F, Fischer U, Yeo NC, Kreienkamp H-J, Lessel D. NM_138615.2(DHX30): c.2174G>A (p. Arg725His). Variant #0000763354. LOVD 3.0. <https://databases.lovd.nl/shared/variants/0000763354>.
 49. Mannucci I, Dang NDP, Huber H, Murry JB, Abramson J, Althoff T, Banka S, Baynam G, Bearden D, Beleza A, Benke PJ, Berland S, Bierhals T, Bilan F, Bindoff LA, Braathen GJ, L. Busk Ø, Chenbhanich J, Denecke J, Escobar LF, Estes C, Fleischer J, Groepper D, Haaxma CA, Hempel M, Holler-Managan Y, Houge G, Jackson A, Kellogg L, Keren B, Kiraly-Borri C, Kraus C, Kubisch C, Le Guyader G, Ljungblad UW, Brenman LM, Martinez-Agosto JA, Might M, Miller DT, Minks KQ, Moghaddam B, Nava C, Nelson SF, Parant JM, Prescott T, Rajabi F, Randrianaivo H, Reiter SF, Schuurs-Hoeijmakers J, Shieh PB, Slavotinek A, Smithson S, Stegmann APA, Tomczak K, Tveten K, Wang J, Whitlock JH, Zweier C, McWalter K, Juusola J, Quintero-Rivera F, Fischer U, Yeo NC, Kreienkamp H-J, Lessel D. NM_138615.2(DHX30): c.2201C>A (p. Ala734Asp). Variant #0000763355. LOVD 3.0. <https://databases.lovd.nl/shared/variants/0000763355>.
 50. Mannucci I, Dang NDP, Huber H, Murry JB, Abramson J, Althoff T, Banka S, Baynam G, Bearden D, Beleza A, Benke PJ, Berland S, Bierhals T, Bilan F, Bindoff LA, Braathen GJ, L. Busk Ø, Chenbhanich J, Denecke J, Escobar LF, Estes C, Fleischer J, Groepper D, Haaxma CA, Hempel M, Holler-Managan Y, Houge G, Jackson A, Kellogg L, Keren B, Kiraly-Borri C, Kraus C, Kubisch C, Le Guyader G, Ljungblad UW, Brenman LM, Martinez-Agosto JA, Might M, Miller DT, Minks KQ, Moghaddam B, Nava C, Nelson SF, Parant JM, Prescott T, Rajabi F, Randrianaivo H, Reiter SF, Schuurs-Hoeijmakers J, Shieh PB, Slavotinek A, Smithson S, Stegmann APA, Tomczak K, Tveten K, Wang J, Whitlock JH, Zweier C, McWalter K, Juusola J, Quintero-Rivera F, Fischer U, Yeo NC, Kreienkamp H-J, Lessel D. NM_138615.2(DHX30): c.2215A>G (p. Thr739Ala). Variant #0000763356. LOVD 3.0. <https://databases.lovd.nl/shared/variants/0000763356>.
 51. Mannucci I, Dang NDP, Huber H, Murry JB, Abramson J, Althoff T, Banka S, Baynam G, Bearden D, Beleza A, Benke PJ, Berland S, Bierhals T, Bilan F, Bindoff LA, Braathen GJ, L. Busk Ø, Chenbhanich J, Denecke J, Escobar LF, Estes C, Fleischer J, Groepper D, Haaxma CA, Hempel M, Holler-Managan Y, Houge G, Jackson A, Kellogg L, Keren B, Kiraly-Borri C, Kraus C, Kubisch C, Le Guyader G, Ljungblad UW, Brenman LM, Martinez-Agosto JA, Might M, Miller DT, Minks KQ, Moghaddam B, Nava C, Nelson SF, Parant JM, Prescott T, Rajabi F, Randrianaivo H, Reiter SF, Schuurs-Hoeijmakers J, Shieh PB, Slavotinek A, Smithson S, Stegmann APA, Tomczak K, Tveten K, Wang J, Whitlock JH, Zweier C, McWalter K, Juusola J, Quintero-Rivera F, Fischer U, Yeo NC, Kreienkamp H-J, Lessel D. NM_138615.2(DHX30): c.2345G>A (p. Arg782Gln). Variant #0000763357. LOVD 3.0. <https://databases.lovd.nl/shared/variants/0000763357>.
 52. Mannucci I, Dang NDP, Huber H, Murry JB, Abramson J, Althoff T, Banka S, Baynam G, Bearden D, Beleza A, Benke PJ, Berland S, Bierhals T, Bilan F, Bindoff LA, Braathen GJ, L. Busk Ø, Chenbhanich J, Denecke J, Escobar LF, Estes C, Fleischer J, Groepper D, Haaxma CA, Hempel M, Holler-Managan Y, Houge G, Jackson A, Kellogg L, Keren B, Kiraly-Borri C, Kraus C, Kubisch C, Le Guyader G, Ljungblad UW, Brenman LM, Martinez-Agosto JA, Might M, Miller DT, Minks KQ, Moghaddam B, Nava C, Nelson SF, Parant JM, Prescott T, Rajabi F, Randrianaivo H, Reiter SF, Schuurs-Hoeijmakers J, Shieh PB, Slavotinek A, Smithson S, Stegmann APA, Tomczak K, Tveten K, Wang J, Whitlock JH, Zweier C, McWalter K, Juusola J, Quintero-Rivera F, Fischer U, Yeo NC, Kreienkamp H-J, Lessel D. NM_138615.2(DHX30): c.2723G>A (p. Arg908Gln). Variant #0000763358. LOVD 3.0. <https://databases.lovd.nl/shared/variants/0000763358>.
 53. Mannucci I, Dang NDP, Huber H, Murry JB, Abramson J, Althoff T, Banka S, Baynam G, Bearden D, Beleza A, Benke PJ, Berland S, Bierhals T, Bilan F, Bindoff LA, Braathen GJ, L. Busk Ø, Chenbhanich J, Denecke J, Escobar LF, Estes C, Fleischer J, Groepper D, Haaxma CA, Hempel M, Holler-Managan Y, Houge G, Jackson A, Kellogg L, Keren B, Kiraly-Borri C, Kraus C, Kubisch C, Le Guyader G, Ljungblad UW, Brenman LM, Martinez-Agosto JA, Might M, Miller DT, Minks KQ, Moghaddam B, Nava C, Nelson SF, Parant JM, Prescott T, Rajabi F, Randrianaivo H, Reiter SF, Schuurs-Hoeijmakers J, Shieh PB, Slavotinek A, Smithson S, Stegmann APA, Tomczak K, Tveten K, Wang J, Whitlock JH, Zweier C, McWalter K, Juusola J, Quintero-Rivera F, Fischer U, Yeo NC, Kreienkamp H-J, Lessel D. NM_138615.2(DHX30): c.347_360del (p. Ala116Valfs*12). Variant #0000763359. LOVD 3.0. <https://databases.lovd.nl/shared/variants/0000763359>.
 54. Mannucci I, Dang NDP, Huber H, Murry JB, Abramson J, Althoff T, Banka S, Baynam G, Bearden D, Beleza A, Benke PJ, Berland S, Bierhals T, Bilan F, Bindoff LA, Braathen GJ, L. Busk Ø, Chenbhanich J, Denecke J, Escobar LF, Estes C, Fleischer J, Groepper D, Haaxma CA, Hempel M, Holler-Managan Y, Houge G, Jackson A, Kellogg L, Keren B, Kiraly-Borri C, Kraus C, Kubisch C, Le Guyader G, Ljungblad UW, Brenman LM, Martinez-Agosto JA, Might M, Miller DT, Minks KQ, Moghaddam B, Nava C, Nelson SF, Parant JM, Prescott T, Rajabi F, Randrianaivo H, Reiter SF, Schuurs-Hoeijmakers J, Shieh PB, Slavotinek A, Smithson S, Stegmann APA, Tomczak K, Tveten K, Wang J, Whitlock JH, Zweier C, McWalter K, Juusola J, Quintero-Rivera F, Fischer U, Yeo NC, Kreienkamp H-J, Lessel D. NM_138615.2(DHX30): c.2389C>T (p. Arg797*). Variant #0000763360. LOVD 3.0. <https://databases.lovd.nl/shared/variants/0000763360>.
 55. Mannucci I, Dang NDP, Huber H, Murry JB, Abramson J, Althoff T, Banka S, Baynam G, Bearden D, Beleza A, Benke PJ, Berland S, Bierhals T, Bilan F, Bindoff LA, Braathen GJ, L. Busk Ø, Chenbhanich J, Denecke J, Escobar LF, Estes C, Fleischer J, Groepper D, Haaxma CA, Hempel M, Holler-Managan Y, Houge G, Jackson A, Kellogg L, Keren B, Kiraly-Borri C, Kraus C, Kubisch C, Le Guyader G, Ljungblad UW, Brenman LM, Martinez-Agosto JA, Might M, Miller DT, Minks KQ, Moghaddam B, Nava C, Nelson SF, Parant JM, Prescott T, Rajabi F, Randrianaivo H, Reiter SF, Schuurs-Hoeijmakers J, Shieh PB, Slavotinek A, Smithson S, Stegmann APA, Tomczak K, Tveten K, Wang J, Whitlock JH, Zweier C, McWalter K, Juusola J, Quintero-Rivera F, Fischer U, Yeo NC, Kreienkamp H-J, Lessel D. NM_138615.2(DHX30): g.47098509_48109065del. Variant #0000763361. LOVD 3.0. <https://databases.lovd.nl/shared/variants/0000763361>.
 56. Mannucci I, Dang NDP, Huber H, Murry JB, Abramson J, Althoff T, Banka S, Baynam G, Bearden D, Beleza A, Benke PJ, Berland S, Bierhals T, Bilan F, Bindoff LA, Braathen GJ, L. Busk Ø, Chenbhanich J, Denecke J, Escobar LF, Estes C, Fleischer J, Groepper D, Haaxma CA, Hempel M, Holler-Managan Y, Houge G, Jackson A, Kellogg L, Keren B, Kiraly-Borri C, Kraus C, Kubisch C, Le Guyader G, Ljungblad UW, Brenman LM, Martinez-Agosto JA, Might M, Miller DT, Minks KQ, Moghaddam B, Nava C, Nelson SF, Parant JM, Prescott T, Rajabi F, Randrianaivo H, Reiter SF, Schuurs-Hoeijmakers J, Shieh PB, Slavotinek A, Smithson S, Stegmann APA, Tomczak K, Tveten K, Wang J, Whitlock JH, Zweier C, McWalter K, Juusola J, Quintero-Rivera F, Fischer U, Yeo NC, Kreienkamp H-J, Lessel D. NM_138615.2(DHX30): g.47882366_47884746del. Variant #0000763362. LOVD 3.0. <https://databases.lovd.nl/shared/variants/0000763362>.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

